Hospital pharmacists don't decide what to stock, they simply respond to physicians' orders. If the docs don't order it, it doesn't get stocked.
As far as SNY, you have to appreciate the HUGE barrier they have to deal with. Afrezza has been declared ONLY non-inferior to humalog. The ONLY selling point SNY has to work with is afrezza's inhalability as a means of avoiding injections. SNY reps can't make ANY other claims beyond that.
I think more significant was the interview with Brandicourt -- transcript on SNY site -- and the fact that HE didn't mention afrezza. He played an important role in exubera's development and launch, and you'd think he express SOMETHING about afrezza and what he thinks of its potential. Not saying anything makes it look like he's already erased it from memory.
"... holding off on any marketing push until EU approval at which time they gain greater reward for their efforts."???? Well, given that they HAVEN'T yet applied for EU approval and have given NO indication when or even IF they plan on applying for EU approval, I don't think that's why they're "holding off on any marketing."
Also consider how dumb it would be to do such a thing. Most countries have socialized medicine and aren't likely to pay up for afrezza -- go back and review what the EU countries said when Pfizer tried to get exubera covered. It would be more rational to "fire all your guns" in the country where you at least have a shot at decent third party reimbursement. Not only do you have the chance to assess REAL consumer demand, but you have a chance for a "leg up" on reimbursement.
Oh, brother, should have seen it coming:
"...a biotech company based in Danbury, said he will talk about two of the treatment areas chosen for the company’s next products in an earnings..."
Notice that he DOESN'T say he will talk about two "drugs" but about "two treatment areas"!
So DON'T expect any new product announcement, just more BS about all the benefits TS could have to neurology, pulmonary, etc.
"...thinking the stock price is a reflection of management and their efforts."????? Uhhhhhhhh...ain't it SUPPOSED to be?
"Is shareholder value something MNKD thinks about?"??? Oh, PLUEEEEEZE! The LAST thing on God's little green planet that ANY biotech management thinks about is "shareholder value"! They're too busy tracking down FREE money to help fund their fat salaries, benefits, bonuses, and perks!
Actually, YOU sound more in a state of "panic" than anyone. Of course, with SSH bouncing around its 52 week LOW, I guess I can't blame you.
"...she still holds some 3800 shares and has not increased the 279 share sale amount since her departure from SSH."???
Seriously? Pardon me a sec:
HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW!!!!
...oh, man! Thanks! I can always use a good laugh! So she's got a WHOPPING 3800 shares and she hasn't changed her 279 share sale amount???? THAT is something to boast about?
Not to mention, since she is NO longer a SSH employee, she is NO longer REQUIRED to file how much she owns, sells, or does otherwise with! For all ANYONE knows she sold everything the day after she was FIRED!
Man, talk about scraping the bottom of the barrel for SOMETHING positive about SSH!
...in Time and People magazines IMPRESSIVE? Made me sit up and take notice! Of course, they WERE for toujeo and NOT afrezza, but SNY has to may some money somehow -- right?
I dunno, this sounds pretty reasonable to me:
"Now to sucker in money from the public, Mann took his company MannKind public, like Second Sight Inc (Nasdaq:EYES), to sucker in people's hard earned cash and retirement savings to fund his dog and pony shows."
Let's face it -- who is the ONE person who has made out like a bandit over the years with MNKD stock and debt?
"...short sellers are beginning to sweat..."??? Jeez! If I hd a nickel for every time I heard that line used in reference to some beaten down stock, I could retire to Tahiti! With MNKD by now they've "sweated" so much they SURELY must be about to turn to DUST!!
Ross Swift was the much ballyhooed "first c-pulse in Britain" last year who so tearjerkingly got to walk down his daughter down the wedding aisle last year. Well, it appears that about four months after he got c-pulse, he got an LVAD -- which by the US trial would make him a FAIL. From the letter "Upgrade Ambulatory Extra-Aortic Counterpulsation to Full-Support LVAD" written by the docs handling the c-pulse "European" trial in Britain at the Royal Brompton & Harefield NHS Foundation Trust., it says, regarding a patient, that "...four months after c-pulse implantation in a patient with underlying history of ischemic heart disease...", he was UPGRADED to an LVAD!
Best I can tell, the dates fit and Mr. Swift is the ONLY known c-pulse recipient in Britain so far.
But even MORE interesting were their complaints of PROBLEMS with "dense adhesions...between the aortic wall and the c-pulse cuff..." when they tried to remove the c-pulse and place the LVAD. Unfortunately, I can't copy and paste the quite a bit more they had to say, but they sounded quite unhappy about it. That may explain why there haven't been any more c-pulse implants in Britain. They conclude by saying that it might be a good idea to avoid patients with "borderline left ventricular function" at risk of future LVAD placement. Unfortunately, that includes pretty much ALL class 3 patients and pretty much puts SSH's entire "customer Base" at risk. Now I'm understanding Rosa's sudden interest in pulmonary hypertension!
Which tells you how DESPERATE SSH to find SOMETHING that c-pulse can actually DO! So far, all they've demonstrated in the pivotal trial is that it would probably be very useful in euthanasia!
So now the "back and fill" starts with one of thr STUPIDEST ideas I ever heard of -- using the c-pulse to "massage" the pulmonary artery to see if it'll reduce pulmonary artery pressure in patients with pulmonary HTN. That HAS to be Rosa's idea! NOBODY else on this planet could come up with anything THAT dumb!
It seems to me that the primary short arguments should be:
1. Diabetics simply don't seem interested in afrezza. Even aside from script numbers, looking through various forums like tudiabetes, diabetes blogs, facebook, there is practically NO discussion of afrezza. Subtract the efforts of "afrezzauser" and his "crew" of half dozen or so and practically no one ever brings it up.
2. Afrezza sales are, in simple fact, pathetic, I doubt there has been a worse launch of a drug in the history of phramaceutical sales. Think the "Edsel" of drugs.
3. MNKD has "obligation" issues. First, it's obligated to repay 100 million bucks in a couple of weeks. Second, it's obligated to buy 150 million bucks -- give or take based on currency translation -- worth of insulin from a European pharma over the next few years. It's obligated to pay 90 million dollars to Deerfield as milestones are reached. There's the 50 million buck obligation to pay Mann Group.
Worst of all it's obligated to use the 175 million dollar "credit line" from SNY to pay its share of the losses on afrezza. The bad thing here is that the loan is secured by ALL of MNKD's assets -- afrezza, all of its insulin, even the Valencia facility. When Valencia is sold ALL of the dough must be used to repay the loan. ALL of MNKD's profits MUST be used to repay the loan. SNY has the option of ACCELERATING loan repayment under certain conditions, but I couldn't find what those are. Any refinancing of the 100 million will almost necessarily be a convert -- even more dilution -- or high interest junk bonds. Since there is no way of forecasting future losses, shareholders are left with their necks on the guillotine, so to speak.
The obvious counterargument are the milestone payments expected from SNY, but since no one knows the requirements to be met and since MNKD insists it can't reveal them -- something I find highly suspicious -- there's no way to anticipate whether they might salvage MNKD's future
Just listen to see if they allow Rosa to speak. If yes, go SHORT! That's all you need to know -- Rosa speaks, go short IMMEDIATELY!
"MannKind's move to increase manufacturing capability is very important and should help bring clarity to what is happening."??? Seriously? Has ANYTHING that's been happening helped bring "clarity" to ANYTHING? In particular, how does the move to increase manufacturing bring anything? For all you know, MNKD did it just so they could announce it and help "pump" the stock before the earnings report.
It's called "obfuscation." At every turn MNKD either gets into some complicated deal that confuses the daylight out of anyone trying to understand it, and THEN they hide behind things like "we can't discuss blah, blah, because of terms of the contract " or "we can't discuss blah, blah because of we don't want to reveal anything to our competitors." It's taken a decade but they now have the "smoke and mirrors" and "dog and pony show" down to an art! Pfeffer is practically a "stockjobber" Van Gogh! All he needs to do now is cut off an ear!